

North Central Cancer Treatment Group

94-72-52: Diagnostic and Prognostic Markers in High-Grade Glioma

Update 1 – October 17, 2008

Summary of Change

Administrative changes

Replacement pages are included. Please incorporate into the protocol and keep this addendum with your protocol.

Title page Updated to reflect Update 1 and revised NCI version date.

Section 6.0 Procedures for Procurement and Handling of Blood Samples for On-Going NCCTG and Mayo High-Grade Glioma Clinical Trials

Page 20: Section 6.12 has been revised to reflect the correct name of the lab that is receiving the samples: Mayo Medical Laboratories (MML) is now referred to as Mayo Clinical Trials Support (MCTS).